Plum Bio acquisition miscarried or implicated in Ipin Bio equity dispute

On August 12,, Meihua Bio (600873, stock bar) announced that the company intends to terminate the acquisition of 100% of The group's sharesa4E
The announcement further explained that the acquisition of assets has occurred affecting the subject matter of the transaction to meet the restructuring conditions, there may be certain risks, from the protection of the interests of all shareholders and maintain market stability, the company decided to terminate the acquisition mattersa4E
It is reported that according to the earlier targeted issuance plan, Meihua Bio plans to issue 660 million shares at a price of 4.73 yuan per share, plus 700 million yuan in cash to buy all shares of Ipin Bio, Ipin Bio bid as high as 3.831 billion yuana4E
On November 15, 2014, Meihua Bio announced that it intends to issue shares and pay 70,000 yuan in cash to nine enterprises, including Tie Xiaorong and Ningxia Yipin Bio, to purchase 100% interest in Ipin BioOn August 12, 2015, the Ministry of Commerce issued the relevant approval documents, and Plum Bio Shares was suspended from August 13, 2015a4E
Speculation that the sale of Meihua Bio miscarried may have been implicated in the Ipin Bio equity disputea4E
　　On the evening of January 27, 2015, Meihua Bio announced that the 44.1849% stake in Ipin Bio was seized by the Chengdu Central Hospital in Sichuan Province on January 8, with a one-year term The reason is that Sichuan Kaiyuan Group Co., Ltd submitted an application for property preservation to the Chengdu Central Court because of its equity transfer dispute with Yipin Group, Ningxia Fengyou Chemical Co., Ltd and Ningxia Fengxi Industrial Co., Ltd., requesting property preservation measures against Iping Group a4E August 12, Plum Bio (600873, stock bar) announced that the company intends to terminate the acquisition of 100% of The group's shares a4E
　　The announcement further explained that the acquisition of assets has occurred affecting the subject matter of the transaction to meet the restructuring conditions, there may be certain risks, from the protection of the interests of all shareholders and maintain market stability, the company decided to terminate the acquisition matters a4E
　　It is reported that according to the earlier targeted issuance plan, Meihua Bio plans to issue 660 million shares at a price of 4.73 yuan per share, plus 700 million yuan in cash to buy all shares of Ipin Bio, Ipin Bio bid as high as 3.831 billion yuan a4E
　　On November 15, 2014, Meihua Bio announced that it intends to issue shares and pay 70,000 yuan in cash to nine enterprises, including Tie Xiaorong and Ningxia Yipin Bio, to purchase 100% interest in Ipin Bio On August 12, 2015, the Ministry of Commerce issued the relevant approval documents, and Plum Bio Shares was suspended from August 13, 2015 a4E
　　Speculation that the sale of Meihua Bio miscarried may have been implicated in the Ipin Bio equity dispute a4E
　　On the evening of January 27, 2015, Meihua Bio announced that the 44.1849% stake in Ipin Bio was seized by the Chengdu Central Hospital in Sichuan Province on January 8, with a one-year term The reason is that Sichuan Kaiyuan Group Co., Ltd submitted an application for property preservation to the Chengdu Central Court because of its equity transfer dispute with Yipin Group, Ningxia Fengyou Chemical Co., Ltd and Ningxia Fengxi Industrial Co., Ltd., requesting property preservation measures against Iping Group a4E
Share it on feed